» Articles » PMID: 22798320

Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension: Results from the Pulmonary Hypertension Registry of the United Kingdom and Ireland

Abstract

Rationale: Incident pulmonary arterial hypertension was underrepresented in most pulmonary hypertension registries and may have a different disease profile to prevalent disease.

Objectives: To determine the characteristics and outcome of a purely incident, treatment-naive cohort of idiopathic, heritable, and anorexigen-associated pulmonary arterial hypertension and to determine the changes in presentations and survival over the past decade in the United Kingdom and Ireland.

Methods: All consecutive newly diagnosed patients from 2001 to 2009 were identified prospectively.

Measurements And Main Results: A total of 482 patients (93% idiopathic, 5% heritable, and 2% anorexigen-associated pulmonary arterial hypertension) were diagnosed, giving rise to an estimated incidence of 1.1 cases per million per year and prevalence of 6.6 cases per million in 2009. Younger patients (age ≤ 50 yrs) had shorter duration of symptoms, fewer comorbidities, better functional and exercise capacity, higher percent diffusing capacity of carbon monoxide, more severe hemodynamic impairment, but better survival compared with older patients. In comparison with the earlier cohorts, patients diagnosed in 2007-2009 were older, more obese, had lower percent diffusing capacity of carbon monoxide,(,) and more comorbidities, but better survival. Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) equation, REVEAL risk score, and Pulmonary Hypertension Connection Registry survival equation accurately predicted survival of our incident cohort at 1 year.

Conclusions: This study highlights the influence of age on phenotypes of incident pulmonary arterial hypertension and has shown the changes in demographics and epidemiology over the past decade in a national setting. The results suggest that there may be two subtypes of patients: the younger subtype with more severe hemodynamic impairment but better survival, compared with the older subtype who has more comorbidities.

Citing Articles

Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox.

Pulido T, de la Cruz-Perez S, Valencia D, Conde R, Lescano A, Zayas N Int J Cardiol Congenit Heart Dis. 2025; 19:100573.

PMID: 40066342 PMC: 11891735. DOI: 10.1016/j.ijcchd.2025.100573.


RPL39 Was Associated With Sex Differences in Pulmonary Arterial Hypertension.

Wang H, Li L, Zhou G, Wang L, Wu Z Can Respir J. 2025; 2025:7139235.

PMID: 39957991 PMC: 11824382. DOI: 10.1155/carj/7139235.


Shear stress unveils patient-specific transcriptional signatures in PAH: Towards personalized molecular diagnostics.

Wittig C, Konig J, Pan X, Aman J, Bogaard H, Yu P Theranostics. 2025; 15(5):1589-1605.

PMID: 39897541 PMC: 11780538. DOI: 10.7150/thno.105729.


Reassessing Pulmonary Hypertension Classification: Utilizing Criteria for Heart Failure with Preserved Ejection Fraction Instead of Pulmonary Arterial Wedge Pressure.

Park D, Fuge J, Kamp J, Harrigfeld B, Berliner D, Hoeper M J Clin Med. 2025; 13(24.

PMID: 39768504 PMC: 11728240. DOI: 10.3390/jcm13247582.


Trends and levels of the global, regional, and national burden of pulmonary arterial hypertension from 1990 to 2021: findings from the global burden of disease study 2021.

Liu L, Li C, Cai J, Kong R, Wang Y, Wang Y Front Med (Lausanne). 2024; 11:1515961.

PMID: 39720660 PMC: 11666447. DOI: 10.3389/fmed.2024.1515961.